NCT06519877

Brief Summary

Osteoporotic fractures are a major but underrecognized problem in men. There is growing evidence that low dietary fiber intake is a modifiable risk factor for age-related bone loss in men. Preclinical and human studies in adolescents and postmenopausal women suggest that dietary fiber intake influences bone metabolism by modulating the gut microbiome to augment intestinal calcium absorption, but it is unclear through what molecular mechanism and whether dietary fiber has the same effects in older men. In this crossover intervention study, the investigators will enroll and follow 30 older male Veterans to evaluate the effects of soluble corn fiber on intestinal calcium absorption and explore the contribution of the gut microbiome.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for phase_2

Timeline
33mo left

Started Jan 2025

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress34%
Jan 2025Jan 2029

First Submitted

Initial submission to the registry

June 20, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 25, 2024

Completed
5 months until next milestone

Study Start

First participant enrolled

January 1, 2025

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2029

Last Updated

February 17, 2026

Status Verified

February 1, 2026

Enrollment Period

4 years

First QC Date

June 20, 2024

Last Update Submit

February 11, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Intestinal fractional calcium absorption

    Dual stable calcium isotopic tracer method

    At week 4 and week 12 of study participation (at the end of each treatment phase x2)

Secondary Outcomes (4)

  • Biochemical markers of bone turnover

    At week 4 and week 12 of study participation (at the end of each treatment phase x2)

  • Calciotropic hormones

    At week 4 and week 12 of study participation (at the end of each treatment phase x2)

  • Gut microbial profiling

    At week 4 and week 12 of study participation (at the end of each treatment phase x2)

  • Adherence, tolerability, and acceptability

    Throughout study period, an average of 12 weeks

Study Arms (2)

Group 1

EXPERIMENTAL

Soluble corn fiber 20g/day x 4 weeks, washout period for 4 weeks, and placebo (maltodextrin) x 4 weeks.

Dietary Supplement: Soluble corn fiber

Group 2

EXPERIMENTAL

Placebo (maltodextrin) 20g/day x 4 weeks, washout period for 4 weeks, and soluble corn fiber x 4 weeks.

Dietary Supplement: Soluble corn fiber

Interventions

Soluble corn fiberDIETARY_SUPPLEMENT

Soluble corn fiber, also referred to resistant maltodextrin, is a type of dietary fiber made from corn starch. Soluble corn fiber is typically used to thicken processed foods and has been marketed as a prebiotic to improve digestive health.

Group 1Group 2

Eligibility Criteria

Age60 Years+
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male Veterans 60 years of age

You may not qualify if:

  • History of malabsorption
  • Hypercalcemia (corrected Ca \> 10.2 mg/dL)
  • Vitamin D insufficiency (25OHD \< 30 ng/mL)
  • Chronic kidney disease stage 3B or worse (CrCl \< 45 mL/min)
  • Severe hypogonadism (AM fasting serum total testosterone \< 150 ng/dL)
  • Daily use of proton pump inhibitor
  • Use of medication(s) known to affect calcium metabolism
  • Use of medications or supplements that could impact gut microbiota in the previous 3 months (antibiotics or commercially available probiotics or prebiotics.
  • Presence of a condition or abnormality that in the opinion of the Investigator that would compromise the safety of the patient or the quality of the data.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

San Francisco VA Medical Center, San Francisco, CA

San Francisco, California, 94121-1563, United States

RECRUITING

Study Officials

  • Karin C Wu, MD

    San Francisco VA Medical Center, San Francisco, CA

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Karin C Wu, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Sachets of soluble corn fiber and placebo will be prepared and assigned randomization numbers by the investigational pharmacist at the San Francisco VA Health Care System. Participants, study staff, and those involved in outcome assessment will be blinded to the group assignment throughout the study.
Purpose
OTHER
Intervention Model
CROSSOVER
Model Details: Participants will be randomized into one of two groups at a 1:1 ratio in random permutated blocks of size 6. Each group will undergo 2 phases of intervention with soluble corn fiber 20g/day for 4 weeks and placebo (maltodextrin) for 4 weeks, with 4-weeks of washout in between. Group 1 will receive soluble corn fiber first followed by placebo, whereas group 2 will receive placebo first followed by soluble corn fiber. Outcomes will be assessed at the end of each intervention phase.
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 20, 2024

First Posted

July 25, 2024

Study Start

January 1, 2025

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

January 1, 2029

Last Updated

February 17, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations